Friedberg Ezra M 4

What Happened Ezra M. Friedberg, a director of Pelthos Therapeutics, sold a total of 283 shares of Pelthos common stock in two open‑market transactions on June 15, 2026. He sold 224 shares at a weighted average price of $27.12 (reported proceeds $6,076) and 59 shares at a weighted average price of $27.94 (reported proceeds $1,648), for combined proceeds of about $7,724. This was a sale (not a purchase); the filing indicates the sales were made pursuant to a prearranged Rule 10b5‑1 plan to satisfy estimated tax obligations related to vested restricted stock units.

Key Details

• Transaction date: June 15, 2026; Form 4 filed June 17, 2026 (filed within the typical two‑business‑day window).
• Shares sold: 224 shares @ $27.12 (weighted avg; trades ranged $26.71–$27.44) and 59 shares @ $27.94 (weighted avg; trades ranged $27.92–$28.00).
• Total proceeds reported: ~$7,724.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Notable footnotes:
  • F1: Sales executed under a Rule 10b5‑1 plan adopted Dec 16, 2025 to satisfy estimated tax obligations from RSU vesting.
  • F2/F3: Each sale was executed in multiple trades; reported prices are weighted averages; detailed trade-by-trade info is available on request.
  • F4: Mr. Friedberg is manager of Balmoral Financial Group LLC and Key Recovery Group LLC; he may be deemed to beneficially own shares held by those entities but disclaims such ownership except to the extent of his pecuniary interest.

Context

• Rule 10b5‑1 plans are prearranged trading programs that allow insiders to sell shares on a schedule and are commonly used for tax or diversification purposes; such sales are generally considered routine and not necessarily an indicator of sentiment about the company.
• Because these transactions were sales to cover taxes from vested RSUs (per the filing), they are categorized as tax‑related and not as new purchases or exercises.